Foundayo Dose Steps 2026: the Oral GLP-1 Ladder

4 min read · doses off DailyMed · last verified October 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

Foundayo is orforglipron, from Eli Lilly, approved on April 1, 2026 for weight management. It is the second GLP-1 tablet licensed for that purpose, after the Wegovy tablet. Unlike oral semaglutide, it is not a peptide, which is why it comes with no fasting window and no elaborate instructions about water.

You take one tablet a day, swallowed whole, and never more than one in a day.

The ladder

The ladder
DoseHold at leastWhat it is
0.8 mg30 daysA run-up rather than a treatment dose. Its purpose is your stomach, not your weight.
2.5 mg30 daysThe first step that is doing something. Stay longer if the nausea has not settled.
5.5 mg30 daysMiddle of the ladder.
9 mg30 daysA perfectly reasonable place to stop if the rungs above disagree with you.
14.5 mg30 daysSecond from top. Staying here is allowed if it works and you tolerate it.
17.2 mg—The maximum, and the dose that produced the headline trial result.

Each step is held a minimum of thirty days, and whether you climb past the middle depends on how you are responding and what you can tolerate. The 17.2 mg dose is the maximum, and you do not have to reach it.

Taking it

  • Food is irrelevant. No empty stomach, no measured sip of water, no waiting before breakfast. This is the clearest practical difference from oral semaglutide. The reason is chemistry: a non-peptide does not need shielding from your digestion.
  • Same time each day, whichever time fits your life.
  • Swallow it whole. Do not split, crush or chew it.
  • One a day, maximum, no matter what happened yesterday.
  • No fridge, no needles.

Interactions: the part that is easy to skip

This is where a tablet is more complicated than an injection. Orforglipron is processed by CYP3A4, so other medicines change its levels and it changes theirs. Injectable GLP-1s are peptides and largely avoid this territory altogether.

  • Strong CYP3A4 inhibitors: your maximum drops to 9 mg a day. If the drug also blocks OATP1B, do not combine them at all.
  • Strong CYP3A4 inducers: avoid. With moderate ones, expect Foundayo to work less well and the dose to need review.
  • Simvastatin: held to 20 mg daily alongside it.
  • Oral contraceptives: the label tells users to switch to a method that is not swallowed or to add a barrier method. That advice covers the first 30 days on the drug and the 30 days after every dose increase. It matters because the drug can harm a developing pregnancy and should stop as soon as one is known about.
  • Other tablets generally: gastric emptying slows, which can change how they are absorbed.

A missed tablet

The label's rule is short, because the schedule is daily.

  • Missed one? Take it as soon as you can, then carry on as usual.
  • Never double up the next dose. It buys nothing and costs you a day of nausea.
  • Missed seven or more days running? Then the climb starts again from a lower dose, per the label, so talk to your prescriber before you resume.

The weekly injections use different windows of four or five days, so do not carry a habit from one to the other.

Reasons to pause and call

  • Severe abdominal pain reaching through to the back. This can be pancreatitis. Stop and get assessed.
  • Pain under the right ribs, fever, or yellowing. Gallbladder disease is a known class effect.
  • Dehydration after prolonged vomiting or diarrhea. Kidney injury has followed this across the class. Hold the next dose, rehydrate and call someone.
  • A new neck lump, hoarseness, difficulty swallowing. The boxed warning covers thyroid C-cell tumors. Anyone with medullary thyroid carcinoma in their history or their family's, or with MEN 2, cannot take this drug at all.
  • Symptomatic low blood sugar, most likely alongside insulin or a sulfonylurea, which may need reducing.
  • Rash, hives, swelling of the face or throat. Emergency care.

The most common complaints are gastrointestinal, and roughly one person in twenty stopped the drug in trials because of them.

Outside this page's scope

  • How well it works. The short answer is 11.1% at the top dose over 72 weeks, which is below both injectable rivals. The longer answer, with the cross-trial caveats that go with it, is in our full write-up.
  • Diabetes. This license covers weight management. Anything else is a separate question.
  • Pregnancy, beyond the fact that this drug and pregnancy do not go together.

Where to go next

References

  1. 1.U.S. National Library of Medicine — DailyMed. FOUNDAYO (orforglipron) tablet — Structured Product Label. DailyMed (FDA-approved labeling, SetID 8ac446c5-feba-474f-a103-23facb9b5c62). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  2. 2.Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025. PMID: 40960239.

Frequently Asked Questions

At least thirty days before any increase, at every rung of the ladder. Holding longer is fine and often sensible if the gastrointestinal effects have not settled. The slow pace is what keeps them manageable, so hurrying tends to backfire.
Take it as soon as you can, then carry on normally, but never double up the next dose. After seven or more missed days running, the label restarts the climb from a lower dose, so check with your prescriber first. The weekly injectables use completely different rules, so do not transfer a habit from one to the other.
No, and that is its main practical advantage. Oral semaglutide is a peptide that struggles to survive digestion, which is why its label demands an empty stomach, a measured sip of water and a wait. Orforglipron is a small molecule and needs none of that: take it at whatever hour suits you, with or without food.
No. It is the maximum permitted, not a target. Whether you climb past the middle of the ladder depends on how you are responding and what you can tolerate, and stopping at 9 mg or 14.5 mg is a legitimate outcome.
More than the injectable GLP-1s do, because it is cleared through CYP3A4 as small molecules are. Strong inhibitors of that enzyme pull your maximum down to 9 mg, strong inducers should be avoided, simvastatin is capped at 20 mg, and anyone using an oral contraceptive is directed onto a non-oral method or told to add a barrier method, during the first 30 days and the 30 days after every increase. Give your prescriber the full list.

Editorial reference content, not medical advice. Changing a dose, holding one, or stopping altogether is a decision for you and your prescriber together. As for the numbers: we checked every dose figure here against the FDA-approved Structured Product Label on DailyMed in October 2026.

Browse all cheat sheets, top-N research lists, or long-form research deep-dives.